Andere talen Cullinan Therapeutics, Inc.

Aandelen

CGEM

US2300311063

Beurs gesloten - Nasdaq Andere beurzen 22:00:01 23-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
16,64 ^USD	+6,49%		-6,91%	+63,35%

16/04	Transcript : Cullinan Oncology, Inc. - Special Call
16/04	Cullinan Oncology, Inc. kondigt belangrijke updates aan over het plan om uit te breiden naar auto-immuunziekten, de wetenschappelijke rationale voor de ontwikkeling van CLN-978 voor auto-immuunziekten	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Cullinan Oncology : Therapeutics Corporate Update	16/04
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases	16/04
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases	16/04
Cullinan Oncology, Inc. Announces Important Updates About Its Plan to Expand into Autoimmune Diseases, the Scientific Rationale for Developing CLN-978 in Autoimmune Diseases	16/04
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement	16/04
Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in funding from a group of investors	15/04
Cullinan Oncology, Inc.(NasdaqGS:CGEM) added to S&P Biotechnology Select Industry Index	18/03
Cullinan Oncology Finance Chief Jeffrey Trigilio to Leave	14/03
Cullinan Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results	14/03
Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024	14/03
Cullinan Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03
North American Morning Briefing : Stock Futures -2-	13/03
Cullinan Oncology Secures FDA Approval for CLN-619's Investigational New Drug Application in Multiple Myeloma	01/03
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma	01/03
Cullinan Oncology to Participate in Upcoming Investor Conferences	27/02
Cullinan Oncology to Participate in Upcoming Investor Conferences	27/02
Cullinan Oncology Insider Sold Shares Worth $647,200, According to a Recent SEC Filing	05/02
Cullinan Oncology Insider Sold Shares Worth $563,600, According to a Recent SEC Filing	31/01
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference	18/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cullinan Therapeutics, Inc.

Aandelen

CGEM

US2300311063

Andere talen

Filters